Mizuho Securities analyst Mara Goldstein maintained a Hold rating on Incyte (NASDAQ:INCY) Corp on Thursday, setting a price target of $95, which is approximately 1.42% below the present share price of $96.37.
Goldstein expects Incyte Corp to post earnings per share (EPS) of -$0.07 for the first quarter of 2021.
The current consensus among 10 TipRanks analysts is for a Moderate Buy rating of shares in Incyte, with an average price target of $98.14.
The analysts price targets range from a high of $120 to a low of $87.
In its latest earnings report, released on 09/30/2020, the company reported a quarterly revenue of $620.64 million and a net profit of $12.45 million. The company's market cap is $21.1 billion.
According to TipRanks.com, Mizuho Securities analyst Mara Goldstein is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 20.7% and a 45.51% success rate.
Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development and commercialization of proprietary therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late stage development, and commercialized products such as JAKAFI (ruxolitinib), and ICLUSIG (ponatinib). The company was founded by Roy A. Whitfield in April 1991 and is headquartered in Wilmington, DE.